News

BioVie Inc. Secures Funding Through Direct Offering and Placement

BioVie Inc. Secures Funding Through Direct Offering and Placement

BioVie Inc. Secures Funding Through Direct Offering and Placement

Announcing a pivotal moment for the company, BioVie Inc. (NASDAQ: BIVI) is making strides in the pharmaceutical landscape with its recently priced registered direct offering. This innovative clinical-stage firm focuses on developing transformative therapies targeting chronic debilitating conditions, notably liver disease and neurological disorders.

Details of the Offering

In this latest offering, BioVie plans to sell approximately 4,443,000 shares of its common stock, priced at $1.50 per share, aiming for an impressive total gross result of $6,664,500 before considering placement agent fees and various related expenses. This capital will be a significant boost for the company as it navigates its ongoing projects.

Warrants and Their Significance

As part of the financing structure, the company will also issue unregistered warrants to investors, providing an opportunity to purchase an equivalent number of common stock shares at a slightly lower price of $1.37 each. These warrants are designed to become exercisable six months post-issuance and will remain valid for five years, adding additional value for shareholders.

Utilization of Proceeds

BioVie intends to allocate the net proceeds primarily toward working capital and general corporate needs, reinforcing its operational foundation. The shares and associated warrants from this direct offering will significantly bolster the company’s financial flexibility as it advances its unique drug therapies.

Expected Closure Timeline

The offering and private placement are projected to close shortly, pending standard contractual conditions. With ThinkEquity serving as the sole placement agent, the transaction is poised to enrich BioVie’s capital resources considerably.

About BioVie Inc.

Delving deeper into the company’s mission, BioVie Inc. is dedicated to pioneering innovative drug therapies, particularly targeting neurological and neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases, along with advanced liver diseases. Their leading candidate, bezisterim, shows promise in curbing neuroinflammation and addressing insulin resistance—key factors in numerous neurodegenerative disorders.

The Fight Against Liver Disease

In parallel, BioVie is developing BIV201, a continuous infusion of terlipressin designated as an Orphan drug. This candidate is currently under FDA Fast Track status and is undergoing discussions to shape its Phase 3 clinical trial designs, primarily aimed at easing complications arising from liver cirrhosis and ascites. The active agent has already gained approval in the U.S. and around 40 other nations for similar advanced liver issues.

Inquiries and Contact

For those interested in learning more, BioVie Inc. encourages reaching out to their dedicated investor relations personnel. Bruce Mackle, the Managing Director at LifeSci Advisors, LLC, is available for inquiries via email.

Media inquiries should be directed to Melyssa Weible, Managing Partner at Elixir Health Public Relations, ensuring clear communication and access to relevant information.

Frequently Asked Questions

What is the purpose of the direct offering by BioVie Inc.?

The direct offering aims to generate capital to support the company's working capital and general corporate purposes.

What details were disclosed about the warrants in the offering?

Investors will receive unregistered warrants to purchase shares at an exercise price of $1.37, exercisable starting six months from issuance.

How much capital is BioVie seeking through this offering?

BioVie is looking to raise approximately $6,664,500 through the registered direct offering priced at $1.50 per share.

What stage is BioVie in regarding their drug development?

BioVie is a clinical-stage company focused on developing innovative therapies for chronic conditions, particularly neurodegenerative disorders and liver disease.

Who is the placement agent for the offering?

ThinkEquity is acting as the sole placement agent for BioVie’s direct offering and private placement.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 49

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 0

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 203

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
Blueprint Strengthens Team with New Capital Markets Director

Updated Category News Views 114

Blueprint Bolsters Its Ranks Hiring Caitlin Novak as Managing Director marks a pivotal step for Blueprint Healthcare Real Estate Advisors. They aren't just swapping pawns; they're making a statement, beefing up their capital markets strategy with a heavy hitter seasoned in steering around fiscal pitfalls. Novak isn’t some rookie wet behind the ears—she's clocked more...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 173

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 269

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 40

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading
Wall Street Gains Hold Amid Volatility Drop

Updated Category News Views 61

A Week of Gains and Regulatory Moves Right out of the gate, it’s been a decent stretch for Wall Street. Weekly gains kept the party going, even as traders navigated the usual hurdles. Stocks finished the week with a solid performance—all the heavy hitters like Dow, S&P 500, Nasdaq, and Russell 2000 ended on a high note, waltzing uphill past where many imagined...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 77

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
e News Articles" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles